- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Concord Biotech Ltd (CONB)
The Concord Biotech share price today is 596.80, view NSE CONB stock exchange data. Track the latest Concord Biotech share price with real-time updates on CONB stock performance including market cap, day range, 52-week range and dividend yield. Access CONB charts, earnings dates and analyst estimates to support your investment decisions.
596.80
-15.40(-2.52%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
592.50
625.20
52 wk Range
493.50
807.50
CONCORDBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
592.50625.20
52 wk Range
493.50807.50
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
CONCORDBIO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
760.50
Upside
+27.43%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Cash flows can sufficiently cover interest payments
Concord Biotech receives Investment Bank Analyst Rating Update- Investing.com
Pro
Why Is Concord Biotech Stock Up by 8% Today?- Trade Brains
- 1
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 760.50
(+27.43% Upside)
Concord Biotech Ltd Earnings Call Summary for Q2/2027
- Concord Biotech Q2 revenue rose 25% YoY to INR 309.1 crore, meeting forecasts, but EPS of 7.0 missed estimates by 1.4%, sending shares down 7.98%.
- Gross margin fell 400 bps to 76.2% due to higher solvent and raw material costs; management expects temporary pressure with recovery as costs normalize.
- Company reaffirmed medium-term EBITDA margin target of 38-40% and FY2027 revenue growth slightly above historical 18-19% pace with strong H1 momentum.
- Growth drivers include immunosuppressants, oncology (revenue nearly doubled YoY), U.S. formulation platform Stellon, and injectables facility ramp-up expected H2.
- Capex guidance set at INR 50-60 crore annually for FY2027-28 for growth projects; dermatology unit Inspira targets INR 400-500 crore revenue in 4-5 years.
Last Updated: 28-10-2026, 05:00 pm
Read Full TranscriptEarnings
Latest Release
27-10-2026
EPS / Forecast
3.40 / 3.55
Revenue / Forecast
3.09B / 2.99B
Compare CONCORDBIO to Peers and Sector
Metrics to compare | CONCORDBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCONCORDBIOPeersSector | |
|---|---|---|---|---|
P/E Ratio | 44.2x | 35.9x | −0.2x | |
PEG Ratio | −3.39 | 0.62 | 0.00 | |
Price/Book | 6.0x | 4.4x | 2.6x | |
Price / LTM Sales | 10.7x | 3.9x | 2.8x | |
Upside (Analyst Target) | 27.4% | 8.0% | 60.9% | |
Fair Value Upside | Unlock | −0.9% | 9.5% | Unlock |
Concord Biotech Limited, a, biopharma company, engages in the research and development, manufacture, and sale of pharmaceutical products in India and internationally. It operates through Active Pharmaceutical Ingredients (APIs) and Formulations segments. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, daptomycin, fusidic acid, colistimethate sodium, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi acetate, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Concord Biotech (CONCORDBIO) Share Price Today?
The Concord Biotech share price today is 596.80.
What is the current Concord Biotech (CONCORDBIO) share price and day range?
As of 10-11-2026, the Concord Biotech share price is 596.80, with a previous close of 596.80. The share price has ranged from 592.50 to 625.20 today, while the 52-week range spans from 493.50 to 807.50.
What Is the Concord Biotech Market Cap?
As of today, Concord Biotech market cap is 124.87B.
Does Concord Biotech Pay Dividends? What's The Current Dividend Yield?
The Concord Biotech dividend yield is 0.6%%.
What Is the Concord Biotech (CONCORDBIO) Share Price Target?
The average 12-month share price target for Concord Biotech is 760.50, with a high estimate of 850 and a low estimate of 680. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +27.43% Upside potential.
What Is Concord Biotech's Earnings Per Share (TTM)?
The Concord Biotech EPS (TTM) is 13.43.
From a Technical Analysis Perspective, Is CONCORDBIO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Concord Biotech Trade On?
Concord Biotech is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Concord Biotech?
The stock symbol for Concord Biotech is "CONCORDBIO."
How Many Times Has Concord Biotech Stock Split?
Concord Biotech has split 1 times.
How Many Employees Does Concord Biotech Have?
Concord Biotech has 1624 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.